Value of pancreatic duct stent placement combined with octreotide for reducing the postoperative pancreatic fistula rate in patients with diabetes undergoing pancreaticoduodenectomy

Table 1 Comparison of baseline data between the two groups of patients after propensity score matching, n (%)/mean ± SD

Index	Combined group (n = 60)	Control group (n = 60)	χ²/t	P value	SMD
					Before matching	After matching
Age (years)	62.5 ± 7.2	61.8 ± 7.5	0.512	0.610	0.359	0.095
Gender			0.138	0.710	0.312	0.067
male	35 (58.33)	33 (55.00)
female	25 (41.67)	27 (45.00)
BMI (kg/m²)	24.2 ± 2.8	23.9 ± 2.9	0.547	0.585	0.342	0.098
Duration of diabetes (year)	8.6 ± 4.2	8.2 ± 4.5	0.501	0.617	0.378	0.092
HbA1c (%)	7.5 ± 1.1	7.4 ± 1.2	0.429	0.669	0.589	0.087
Pancreatic texture			0.134	0.714	0.325	0.067
soft	27 (45.00)	29 (48.33)
hard	33 (55.00)	31 (51.67)
Main pancreatic duct diameter (mm)	2.8 ± 0.9	2.7 ± 0.8	0.608	0.544	0.321	0.095
Intraoperative blood loss (mL)	325.6 ± 112.3	332.4 ± 115.7	0.317	0.752	0.165	0.060
Operation time (minute)	318.5 ± 42.6	323.1 ± 45.2	0.571	0.569	0.231	0.098
Combined vascular resection			0.162	0.689	0.308	0.072
Yes	10 (16.67)	8 (13.33)
No	50 (83.33)	52 (86.67)
Pathological type			0.702	0.705	0.362	0.064
Pancreatic head carcinoma	29 (48.33)	27 (45.00)
Periampullary carcinoma	24 (40.00)	26 (43.33)
Benign pancreatic lesions	7 (11.67)	7 (11.67)
Anastomotic characteristics			0.156	0.693	0.324	0.061
Conventional suture group	30 (50.00)	28 (46.67)
Fine suture group	30 (50.00)	32 (53.33)

BMI: Body mass index.

Table 2 Comparison of the number of days of drainage tube indwelling and the number of days of postoperative hospitalization between the two groups, mean ± SD

Index	Combined group (n = 60)	Control group (n = 60)	t	P value
Number of days for drainage tube to remain in place	8.8 ± 3.5	12.1 ± 4.8	2.391	0.018
Postoperative hospital stay	14.5 ± 5.3	19.2 ± 7.1	2.254	0.026

Table 3 Comparison of postoperative glucose metabolism related indicators between the two groups, n (%)/mean ± SD

Index	Combined group (n = 60)	Control group (n = 60)	t/χ²	P value
Mean blood glucose (mmol/L)	8.7 ± 1.4	8.5 ± 1.3	0.802	0.424
Blood glucose CV (%)	24.5 ± 4.1	23.2 ± 3.8	0.997	0.318
Average daily insulin dosage (U/day)	38.6 ± 9.2	37.4 ± 8.8	0.735	0.463
Number of hypoglycemic events	1 (1.7)	0 (0.0)	1.008	0.315

CV: Coefficient of variation.

Table 4 Occurrence of adverse reactions in the two groups of patients, n (%)

Adverse reactions	Combined group (n = 60)	Control group (n = 60)	χ²	P value
Mild diarrhea	3 (5.0)	2 (3.3)	0.210	0.647
Mild nausea	2 (3.3)	1 (1.7)	0.345	0.557
Overall incidence of adverse reactions	5 (8.3)	3 (5.0)	0.536	0.464